AI-generated summary
The authors reviewed nine studies, one preclinical and eight clinical, of transcranial photobiomodulation in autism, ADHD and Down syndrome. They report improvements in several outcomes, such as social communication, attention and motor skills, with minimal adverse effects. The authors call for larger, randomized sham-controlled trials to confirm these findings.
- Studies included
- 9
- Who or what was studied
- Individuals with autism spectrum disorder, attention-deficit/hyperactivity disorder or Down syndrome, plus one animal model
- Wavelengths
- 635, 905 nm
- Limits stated in the abstract
- The abstract describes a narrative review that calls for larger, randomized sham-controlled trials, implying the current evidence is limited.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635-905 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Attention-deficit/hyperactivity disorder, Transcranial photobiomodulation, Neuroinflammation, Oxidative stress, Near-infrared, Biomarker, Autism. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.